← Back to Search

Urethral Expander System

ProVee Urethral Expander System for Benign Prostatic Hyperplasia (ProVIDE Trial)

Verified Trial
Research Sponsored by ProVerum Medical
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Do you live full-time in the zip code that you provided?
Have you been told that you have an enlarged prostate?
Screening 3 weeks
Treatment Varies
Follow Up procedure to 12 months
Awards & highlights

ProVIDE Trial Summary

This trial is studying a device to treat urinary obstruction caused by an enlarged prostate.

Who is the study for?
Men with symptoms of urinary obstruction due to benign prostatic hyperplasia (BPH), who haven't had prostate/bladder cancer, urinary stones, blood in urine recently, or prior prostate procedures. Candidates should not be on medications like finasteride or dutasteride for urination issues and have a prostate size between 30 cc and 80 cc.Check my eligibility
What is being tested?
The trial is testing the ProVee Urethral Expander System's safety and effectiveness compared to a standard urethral access sheath in men with BPH-related urinary problems. The goal is to see if this new device can improve symptoms by expanding the urethra.See study design
What are the potential side effects?
Potential side effects may include discomfort during insertion, risk of infection, possible injury to the urethra or surrounding tissues, bleeding, and temporary increased difficulty with urination.

ProVIDE Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I have been diagnosed with an enlarged prostate.

ProVIDE Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~procedure - 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and procedure - 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Effectiveness: Symptoms Improvement
Safety: Device or Procedure Related Serious Adverse Events
+1 more

ProVIDE Trial Design

3Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: Crossover ProVee Urethral Expander SystemExperimental Treatment1 Intervention
All subjects shall be unblinded following the 3 month follow-up visit. Those subjects randomized to the Sham Arm will be given the opportunity to "crossover" to the ProVee Urethral Expander System.
Group II: Device: The ProVee Urethral Expander SystemActive Control1 Intervention
The ProVee Urethral Expander System consists of two components: a nitinol Expander implant and a 19Fr Delivery System designed to allow the Expander to be deployed under direct vision for the treatment arm.
Group III: Sham: Ureteroscope and urethral access sheathPlacebo Group1 Intervention
An ureteroscope housed within the inner lumen of an urethral access sheath will be used under direct vision for the Sham procedure.

Find a Location

Who is running the clinical trial?

ProVerum MedicalLead Sponsor
2 Previous Clinical Trials
50 Total Patients Enrolled

Media Library

ProVee Urethral Expander System (Urethral Expander System) Clinical Trial Eligibility Overview. Trial Name: NCT05186740 — N/A
Benign Prostatic Hyperplasia Research Study Groups: Crossover ProVee Urethral Expander System, Device: The ProVee Urethral Expander System, Sham: Ureteroscope and urethral access sheath
Benign Prostatic Hyperplasia Clinical Trial 2023: ProVee Urethral Expander System Highlights & Side Effects. Trial Name: NCT05186740 — N/A
ProVee Urethral Expander System (Urethral Expander System) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05186740 — N/A
Benign Prostatic Hyperplasia Patient Testimony for trial: Trial Name: NCT05186740 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the cap on enrollment for this medical experiment?

"Indeed, the information that is posted on clinicaltrials.gov indicates that this trial has resumed its recruitment process. This study was first published on June 9th 2022 and most recent updated on July 25th 2022; thus far, 225 patients have been enrolled from two medical sites."

Answered by AI

Is enrollment still open for this research initiative?

"According to information found on clinicaltrials.gov, enrollment for this trial is ongoing and the investigation was launched on June 9th 2022 with a subsequent update being released in July 25th of that year."

Answered by AI

Who else is applying?

What state do they live in?
How old are they?
What site did they apply to?
Urology Austin
Sheldon Freedman MD
Avant Concierge Urology
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?

Why did patients apply to this trial?

Hopeful for a solution. I like to help science. I don’t take medications. Finestrride doesn’t help.
PatientReceived 1 prior treatment
natural way to get it up.
PatientReceived 2+ prior treatments

What questions have other patients asked about this trial?

What’s it s details? is it trans urethral? How quickly can we start? when will i be contacted?
PatientReceived 2+ prior treatments
Is this similar to urolift?
PatientReceived 1 prior treatment

How responsive is this trial?

Most responsive sites:
  1. Sheldon Freedman MD: < 24 hours
  2. Avant Concierge Urology: < 24 hours
Typically responds via
Phone Call
Average response time
  • < 2 Days
~84 spots leftby Feb 2025